Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Sector Considers New Funding Vehicle: FDA Priority Review Voucher

This article was originally published in The Pink Sheet Daily

Executive Summary

Big Pharma execs say vouchers may be worth $100 million to $200 million. Two small-cap biotechs among those hoping to cash in.

You may also be interested in...



Priority Review Voucher Program Relies On Perceptions, BVGH Head Warns

Coartem may not be perfect test case for advocates of incentive program.

Priority Review Voucher Program Relies On Perceptions, BVGH Head Warns

Coartem may not be perfect test case for advocates of incentive program.

Priority Review Vouchers One Step Closer, But Congress Must Act Again

FDA will not be able to review applications covered by a priority review voucher until it receives Congressional authorization to collect a special user fee to support the program, the agency says in a draft guidance on the new incentive for pharmaceutical companies

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel